Serum paraoxonase activity changes in uremic and kidney-transplanted patients

Nephron

Volumn 83, Issue 2, 1999, Pages 126-131

  Paragh, György ^a   Asztalos, László ^a   Seres, Ildikó ^a   Balogh, Zoltán ^a   Löcsey, Lajos ^b   Kárpáti, István ^a   Mátyus, János ^a   Katona, Evelin ^a   Harangi, Mariann ^a   Kakuk, György ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b Kenezy Teaching Hospital   (Hungary)

Author keywords

Hemodialysis; High density lipoprotein; Kidney transplantation; Paraoxonase; Uremia

Indexed keywords

APOLIPOPROTEIN A; ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY TRANSPLANTATION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; UREMIA;

ADULT; ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; CHOLESTEROL; ESTERASES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIPIDS; MALE; MIDDLE AGED; PHENOTYPE; TRIGLYCERIDES; UREMIA;

EID: 0032865342     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000045489     Document Type: Article

References (43)

1. Morris PJ, Chapman JR, Allen RD, Ting A, Thompson JF, Dunnill MS, Wood RF: Cyclosporine conversion versus conventional immunosuppression: Long-term follow-up and histological evaluation. Lancet 1987;i:586-591.
2. Sutherland DER, Fryd DS, Strand MH, Canafax DM, Ascher NL, Payne WD, Simmons RL, Najarian JS: Results of the Minnesota randomized trial of cyclosporine versus azathioprineantilymphocyte globulin for immunosuppression in renal allograft recipients. Am J Kidney Dis 1985;5:318-327.
3. Larsson O, Attman PO, Blohme I, Nyberg G, Brynger H: Morbidity and mortality in diabetic and non-diabetic recipients of living related donor kidneys. Nephrol Dial Transplant 1987; 2:109-116.
4. Vathsala A, Weinberg RB, Schoenberg L, Grevel J, Goldstein RA, Von Buren CT, Lewis RM, Kahan BD: Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients. Transplantation 1989;48:37-43.
5. Harris KPG, Russell GI, Parvin SD, Veitch PJ, Walls J: Alterations in lipid and carbohydrate metabolism attributable to cyclosporine A in renal transplant recipients. Br Med J (Clin Res Ed) 1986;292:16.
6. Ballantyne CM, Podet EJ, Patsch WP, Harati Y, Appel V, Gotto AM Jr, Youing JB: Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 1989;262:53-56.
7. Attman P, Alaupovic P, Gustafson A: Serum apolipoproteins of patients with chronic renal failure. Kidney Int 1987;32:368-375.
8. Fuh MMT, Lee CM, Jeng CY, Shen DC, Shieh SM, Reaven GM, Chen YD: Effect of chronic renal failure on high density lipoprotein kinetics. Kidney Int 1990;37:1295-1300.
9. Howard BV: Lipoprotein metabolism in diabetes mellitus. J Lipid Res 1987;28:613-628.
10. Kasiske BL, Umen AJ: Persistent hyperlipidemia in renal transplant patients. Medicine 1987;66:309-316.
11. Jackson JM, Lee HA: The role of propranolol therapy and proteinuria in etiology of post renal transplantation hyperlipidemia. Clin Nephrol 1982;18:95-100.
12. Appel G: Lipid abnormalities in renal disease. Kidney Int 1991;39:169-183.
13. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL: Beyond cholesterol: Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320: 915-924.
14. Aviram M: Beyond cholesterol: Modifications of lipoproteins and increased atherogenicity; in Neri GG, Serneri GF, Gensini R, Abbate D, Prisco D (eds): Atherosclerosis, Inflammation and Thrombosis. Florence, Scientific Press. 1993, pp 15-36.
15. Brown MS, Goldstein JL: Lipoprotein metabolism in the macrophage: implication for cholesterol deposition in atherosclerosis. Annu Rev Biochem 1983;52:223-261.
16. Ross R: The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993;362: 801-809.
17. Badimon JJ, Fuster V, Chesebro JH, Badimon L: Coronary atherosclerosis. A multifactorial disease. Circulation 1993:87(suppl II):3-16.
18. Witztum JL, Steinberg D: Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991;88:1785-1792.
19. Aviram M: Modified forms of LDL and atherosclerosis. Atherosclerosis 1993;98:1-9.
20. Aviram M: Macrophage-mediated oxidation of LDL and atherosclerosis; in Bellomo G, Finardi G, Maggi E, Rice-Evans C (eds): Free Radicals Lipoprotein Oxidation and Atherosclerosis: Biological and Clinical Aspects. London, Richelieu Press, 1995, vol 9, pp 101-137.
21. Aviram M: Oxidative modification of low density lipoprotein and atherosclerosis. Isr J Med Sci 1995;31:241-249.
22. Mackness MI, Arrol S, Durrington PN: Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286:152-154.
23. Mackness MI, Abbott CA, Arrol S, Durrington PN: The role of high density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J 1993;294:829-835.
24. Mackness MI, Arrol S, Abbott CA, Durrington PN: Protection of low-density lipoprotein against oxidative modification by high density lipoprotein associated paraoxonase. Atherosclerosis 1993;104:129-135.
25. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ, Brown MJ: Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781-785.
26. Steinberg D, Lewis A, Conner memorial lecture: Oxidative modification of LDL and atherogenesis. Circulation 1997;95:1062-1071.
27. La Du BN, Eckerson HW: The polymorphic paraoxonase/arylesterase isoenzymes of human serum. Fed Proc 1984;43:2338-2341.
28. Ruiz J, Blanché H, James WR, Blatter Garin MC, Vaisse C, Charpentier G, Cohen N, Morabia A, Passa P, Froguel P: G1n-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995;346: 869-872.
29. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN: Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vase Biol 1995;15:1812-1818.
30. Schiavon R, De Fanti E, Giavarina D, Biasioli S, Cavalcanti G, Guidi G: Serum paraoxonase activity decreased in uremic patients. Clin Chim Acta 1996;247:71-80.
31. Paragh G, Seres I, Balogh Z, Varga Zs, Kárpáti I, Mátyus J, Újhelyi L, Kakuk Gy: The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia. Nephron 1998;80:166-170.
32. Furlong CE, Richter RJ, Seidel SL, Costa LG, Motulsky AG: Spectrophotomelric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/arylesterase. Anal Biochem 1989; 180:242-247.
33. Lindner A, Charra B, Sherrard DJ, Scribner BH: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974;290:697-701.
34. Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H: Roles of hypalbuminemia and lipoprotein lipase on hyperlipoproteinaemia in continuous ambulatory peritoneal dialysis. Metabolism 1991;40:1002-1008.
35. Bagdade JD. Albers JJ: Plasma high-density lipoprotein concentrations in chronic hemodialysis and renal transplant patients. N Engl J Med 1977;296:1436-1439.
36. Norbeck HE, Oro L, Carlson LA: Serum lipoprotein concentration in chronic uremia. Am J Clin Nutr 1978;31:1881-1885.
37. Shoji T, Nishizawa Y, Kawagishi T, Tanaka M, Kawasaki K, Tabata T, Inouc T, Morii H: Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis. Atherosclerosis 1997;131:229-236.
38. Chan MK, Ramdial L, Varghese Z, Persaud JW, Fernando ON, Moorhead JF: Plasma LCAT activities in renal allograft recipients. Clin Chim Acta 1982;124:187-193.
39. Savdie E, Gibson JC, Stewart JH, Simmons LA: High density lipoproteins in chronic renal failure and after renal transplantation. Br Med J 1979;i:928-930.
40. Curtis JJ, Galla JH, Woodward SY, Lucas BA, Luke RG: Effect of alternate day prednisone on plasma lipids in renal transplant recipients. Kidney Int 1982;22:42-47.
41. Lacour B, Roullet JB, Beyne P, Kreis H, Thevenin M, Drücke T: Comparison of several atherogenicity indices by the analysis of serum lipoprotein composition in patients with chronic renal failure with or without hemodialysis, and in renal transplant patients. J Clin Chem Clin Biochem 1985;23:805-810.
42. Watson AD, Berliner JA, Hama SY, La Du BN, Fauel KF, Fogelman AM, Navab M: Protective effect of high density lipoprotein associated paraoxonase-inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995;96:2882-2891.
43. Blatter Garin MC, James RW, Dussoix P, Blanche H, Passa P, Froguel P, Ruiz J: Paraoxonase polymorphism Met-Leu 54 is associated with modified serum concentrations of the enzyme: A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 1997;99:62-66.